Fig. 2From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA studyPatients’ illness perception, assessed by BIPQ at baseline (cross-sectional population). *P = 0.041 for perennial vs seasonal asthma patients; p values are non-significant for the remaining components. P-values were calculated using Wilcoxon test. BIPQ, Brief Illness Perception QuestionnaireBack to article page